News | December 13, 2025
Merck wins key EU backing to expand use of PAH Drug WINREVAIR
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Surgical site infections and antimicrobial resistance remain major challenges globally
Millions of stroke survivors across the world may soon have a new defense
The therapy -- Ryoncil (remestemcel-L-rknd) -- will be tested in adults with severe steroid-refractory acute graft-versus-host disease
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
These initiatives will harness top scientific talent and advanced AI technologies to develop new ways to slow the rise of drug-resistant infections
_256_384.png)
India presents one of the world’s largest untapped opportunities for neurovascular screening
Subscribe To Our Newsletter & Stay Updated
